Remove trial restrictions Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Moodys
Dow
Mallinckrodt
Baxter

Last Updated: May 17, 2022

CLINICAL TRIALS PROFILE FOR GLECAPREVIR; PIBRENTASVIR


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Glecaprevir; Pibrentasvir

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02441283 ↗ A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530 Completed AbbVie Phase 2/Phase 3 2015-06-22 This was a long-term follow-up study to evaluate the durability of sustained virologic response (SVR), persistence of direct-acting antiviral agent (DAA) resistance, and clinical outcomes for participants who received glecaprevir (ABT-493) and/or pibrentasvir (ABT-530) in prior AbbVie Phase 2 or 3 clinical studies for the treatment of chronic hepatitis C virus (HCV) infection.
NCT02634008 ↗ Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P Recruiting AbbVie Phase 3 2016-06-01 An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently acquired hepatitis C virus infection with or without HIV co-infection.
NCT02634008 ↗ Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P Recruiting Kirby Institute Phase 3 2016-06-01 An open label, multicentre, international pilot study of paritaprevir/ritonavir, ombitasvir, dasabuvir with or without ribavirin or glecaprevir/pibrentasvir for people with recently acquired hepatitis C virus infection with or without HIV co-infection.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Glecaprevir; Pibrentasvir

Condition Name

Condition Name for Glecaprevir; Pibrentasvir
Intervention Trials
Hepatitis C 11
Hepatitis C Virus (HCV) 9
End Stage Renal Disease 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Glecaprevir; Pibrentasvir
Intervention Trials
Hepatitis C 28
Hepatitis 26
Hepatitis A 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Glecaprevir; Pibrentasvir

Trials by Country

Trials by Country for Glecaprevir; Pibrentasvir
Location Trials
United States 144
Canada 27
Australia 21
China 17
Korea, Republic of 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Glecaprevir; Pibrentasvir
Location Trials
Massachusetts 10
California 10
New York 10
Maryland 9
Pennsylvania 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Glecaprevir; Pibrentasvir

Clinical Trial Phase

Clinical Trial Phase for Glecaprevir; Pibrentasvir
Clinical Trial Phase Trials
Phase 4 8
Phase 3 13
Phase 2/Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Glecaprevir; Pibrentasvir
Clinical Trial Phase Trials
Completed 13
Recruiting 8
Active, not recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Glecaprevir; Pibrentasvir

Sponsor Name

Sponsor Name for Glecaprevir; Pibrentasvir
Sponsor Trials
AbbVie 16
Kirby Institute 4
Massachusetts General Hospital 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Glecaprevir; Pibrentasvir
Sponsor Trials
Other 27
Industry 17
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Dow
Baxter
Mallinckrodt
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.